comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-09 19:32:32 - browse：841

A view of different flags of the European Union Members. -- first opinion coverage from STAT — Ronald Wittek, Pool Photo via AP

Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices varies widely across Europe, making it more challenging for biopharma companies to efficiently launch products in multiple countries and contributing to the disparities in access across the continent.

But change is on the horizon: In less than 15 months, the European Union will establish and begin to implement a standardized, pan-EU framework, which all 27 of member states will be required to use to assess the clinical evidence of newly submitted products or devices. A key pillar of the EU’s Regulation on Health Technology Assessment (HTA), the Joint Clinical Assessment (JCA) aims to establish a single, transparent process to reduce redundant practices and bring life science innovation faster to patients in Europe — no matter where they live.

In a longstanding problem in Europe, access to — and the availability of — medication varies across the member states. For example, in Germany, 87% of products approved by the European Medicines Agency (EMA) have full availability (the product gained access on the public reimbursement list without any restrictions to the patient population). In Poland, that figure drops to 8%, according to a report published by the European Federation of Pharmaceutical Industries. Meanwhile, there is a tremendous difference in the gap between an oncology therapy receiving marketing authorization and a formal positive reimbursement decision, ranging from an average of 86 days in Denmark to 981 days in Latvia.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Lack of health data on LGBTQ+ people has serious consequences

hotspot

WSS

JPM pitch from hospitals? Revenue streams outside of patient care

Ozempic has benefits for kidney disease as well as diabetes

Medicare Advantage coverage denials need scrutiny, senators say

Stem cell biologist probes earliest stages of human development

Immune cells and nerve overgrowth may explain recurring UTI pain

Ozempic has benefits for kidney disease as well as diabetes

knowledge

comprehensive

focus

Tori Bowie and the unacceptable rates of Black maternal death

Fetal cell organoids grown from amniotic fluid, study finds

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

He's 19 months old and has one of the world’s rarest diseases

Sports medicine is finally prioritizing gender equality

Stem cell biologist probes earliest stages of human development

How one medical school became remarkably diverse

Why Talkspace is targeting Medicare, a tricky market

The high cost of giving birth even with insurance

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

hotspot

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Life science postdocs should get big pay hike, NIH panel says

Medicare drug price negotiation continues, as pharma counteroffers

Stories you might have missed in 2023: health, science, medicine

Readout Newsletter: BridgeBio, Akero, and human embryo models

focus

explore

hotspot

focus